Innovative Science

There is an urgent need for therapies to treat or prevent devastating viral diseases in immunocompromised patients with T cell deficiencies who have limited or no treatment options.

We develop allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidates designed to treat or prevent life-threatening viral diseases.

One manufacturing run from a single donor can generate hundreds of doses of VSTs.

In healthy individuals, T cells from the body’s natural defense system provide protection against devastating viruses. For patients with T cell deficiencies, viruses may be uncontrolled, leading to potentially devastating and life-threatening consequences.
T cells from healthy patients with the right characteristics are activated, expanded, and preserved for use on patients in need.
Our allogeneic, off-the-shelf VST therapy candidates benefit patients with T cell deficiencies including transplant recipients, immunocompromised cancer patients, the elderly, and the very young at a higher risk of the devastating consequences of viral disease.
BK Virus
Cytomegalovirus
Adenovirus
Epstein-Bar Virus
Human Herpesvirus-6
Parainfluenza Virus
Human Metapneumovirus
Influenza Virus
Respiratory Syncytial Virus
SARS-CoV-2
Hepatitis B Virus
Human Herpesvirus-8
Bladder
Severe hemorrhagic cystitis
Urinary obstruction
Cystectomy
Brain
Severe encephalitis
Seizure
Memory defect
Progressive Multifocal Leukoencephalopathy
Kidneys
Nephritis
Acute/chronic renal failure
End stage renal disease
Lungs
Pneumonia
Bronchitis
Respiratory failure
Eyes
Retinitis
Blindness
Liver
Chronic hepatitis
Liver cirrhosis
Hepatocellular Carcinoma
Small/Large Intestine
Colitis
Ulceration / perforation
Intestinal bleeding
Malignancy
Kaposi sarcoma
Primary Effusion
Lymphoma (PEL)

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
view

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?